A patent review of EZH2 inhibitors from 2017 and beyond

References

• Cardoso C, Mignon C, Hetet G, et al. The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders. Eur J Hum Genet. 2000;8(3):174–180. DOI:10.1038/sj.ejhg.5200439
   PubMed Web of Science ®Google Scholar
• Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res-Funda Mol Mech Muta. 2008;647(1–2):21–29.
   PubMed Web of Science ®Google Scholar
• Duan R, Du WF, Guo WJ. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020;13(1). DOI:10.1186/s13045-020-00937-8
   Web of Science ®Google Scholar
• Tomassi S, Romanelli A, Zwergel C, et al. Polycomb repressive complex 2 modulation through the development of EZH2-EED interaction inhibitors and EED binders. J Med Chem. 2021;64(16):11774–11797. DOI:10.1021/acs.jmedchem.1c00226
   PubMed Web of Science ®Google Scholar
• Brown ZZ, Muller MM, Jain SU, et al. Strategy for “detoxification” of a cancer-derived histone mutant based on mapping its interaction with the methyltransferase PRC2. J Am Chem Soc. 2014;136(39):13498–13501. DOI:10.1021/ja5060934
   PubMed Web of Science ®Google Scholar
• Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature. 2011;469(7330):343–349.
   PubMed Web of Science ®Google Scholar
• Li BH, Chng WJ. EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications. J Hematol Oncol. 2019;12(1). DOI:10.1186/s13045-019-0814-6
   Web of Science ®Google Scholar
• Xia J, Li JY, Tian L, et al. Targeting enhancer of zeste homolog 2 for the treatment of hematological malignancies and solid tumors: candidate structure-activity relationships insights and evolution prospects. J Med Chem. 2022;65(10):7016–7043. DOI:10.1021/acs.jmedchem.2c00047.
   PubMed Web of Science ®Google Scholar
• Montgomery ND, Yee D, Chen A, et al. The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation. Curr Biol. 2005;15(10):942–947. DOI:10.1016/j.cub.2005.04.051
   PubMed Web of Science ®Google Scholar
• Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Molecular Cell. 2004;15(1):57–67.
   PubMed Web of Science ®Google Scholar
• Sneeringer CJ, Scott MP, Kuntz KW, et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci USA. 2010;107(49):20980–20985.
   Google Scholar
• McGrath J, Trojer P. Targeting histone lysine methylation in cancer. Pharmacol Ther. 2015;150:1–22.
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Hung MC. Regulation and Role of EZH2 in Cancer. Cancer Res Treat. 2014;46(3):209–222.
   PubMed Web of Science ®Google Scholar
• Beguelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center formation and somatic ezh2 mutations promote lymphoid transformation. Cancer Cell. 2013;23(5):677–692. DOI:10.1016/j.ccr.2013.04.011
   PubMed Web of Science ®Google Scholar
• Margueron R, GH L, Sarma K, et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Molecular Cell. 2008;32(4):503–518. DOI:10.1016/j.molcel.2008.11.004
   PubMed Web of Science ®Google Scholar
• Mochizuki-Kashio M, Aoyama K, Sashida G, et al. Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner. Blood. 2015;126(10):1172–1183. DOI:10.1182/blood-2015-03-634428
   PubMed Web of Science ®Google Scholar
• Kuntz KW, Campbell JE, Keilhack H, et al. The importance of being me: magic methyls, methyltransferase inhibitors, and the discovery of tazemetostat. J Med Chem. 2016;59(4):1556–1564. DOI:10.1021/acs.jmedchem.5b01501
   PubMed Web of Science ®Google Scholar
• Knutson SK, Warholic NM, Wigle TJ, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci USA. 2013;110(19):p. 7922–7927.
   Google Scholar
• Epizyme. Inc. Combination therapy for treating cancer. AU. 2017;2017254925.
   Google Scholar
• Medshine Discovery Inc. Biphenyl compound serving as EZH2 inhibitor. WO 2017174023, 2017.
   Google Scholar
• Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nature Genet. 2010;42(2):124–181. DOI:10.1038/ng.518
   Web of Science ®Google Scholar
• Hefei Institutes of Physical Science, Chinese Academy of Science. EZH2 inhibitor and use thereof. WO 2018133795, 2018.
   Google Scholar
• Glaxo Smith Kline Llc. Enhancer of zeste homolog 2 inhibitors. US 20180207144, 2018.
   Google Scholar
• Daiichi Sankyo Company, Limited. 1,3-benzodioxole derivative. US 20180282313, 2018.
   Google Scholar
• Suzhou Sinovent Pharmaceuticals Co Ltd. Polysubstituted benzene compound and preparation method and use thereof. WO 2020020374, 2020.
   Google Scholar
• Shanghai Synergy Pharmaceutical Sciences Co Ltd. Preparation method for amide compound and application thereof in field of medicine. 2020192650, 2020.
   Google Scholar
• Constellation Pharmaceutical Inc. Synthesis of inhibitors of EZH2 WO 2018075598, 2017.
   Google Scholar
• Shanghai Haihe Pharmaceutical Co Ltd, Shanghai Institute of Materia Medical, Chinese Academy of Sciences. Pyrido five-element aromatic ring compound, preparation method therefor and use thereof. WO 2018045971. 2017
   Google Scholar
• Sichuan University, Apeloa Pharmaceutical Co Ltd. Indazol-carboxamide-pyridinone derivatives as well as preparation method and applications thereof. CN 107573327, 2017.
   Google Scholar
• Shanghai Haihe Pharmaceutical Co Ltd. Pyrimido five-membered aromatic heterocyclic compounds as well as preparation method and application thereof. CN 110229157, 2018.
   Google Scholar
• Shanghai Haihe Pharmaceutical Co Ltd. Indolizine compounds as well as preparation method and application thereof. WO 2019170063, 2019.
   Google Scholar
• Jiangsu Hengrui Medicine Co Ltd. Shanghai Hengrui Pharmaceutical Co Ltd. Benzofuran derivative, preparation method thereof and use thereof in medicine. US 20200354349, 2020.
   Google Scholar
• Sichuan Haisco Pharmaceutical Co Ltd. Inhibitors of ZESTE enhancer homolog 2 and uses thereof. CN 114085211, 2021.
   Google Scholar
• Shanghai Synergy Pharmaceutical Sciences Co Ltd. Zhejiang Huahai Pharmaceutical Co Ltd. Preparation method of benzoxazole compound and application of benzoxazole compound in field of medicine. CN. 113666920: 2021.
   Google Scholar
• Sichuan Haisco Pharmaceutical Co Ltd. Azaindole derivative as well as preparation method and application thereof. CN113816950, 2021.
   Google Scholar
• Sichuan University, Apeloa Pharmaceutical Co Ltd. Benzoheterocycle-carboxamide-pyridone derivatives and preparation method and applications thereof. CN. 2017;107573336.
   Google Scholar
• Shanghai Institute of Materia Medical, Chinese Academy of Sciences. EZH2 inhibitor as well as preparation of EZH2 inhibitor and application of EZH2 inhibitor in anti-tumor treatment. CN 110016014, 2018.
   Google Scholar
• Hanmi Pharm Co Ltd. Novel heterotricyclic derivative compound and use of same. WO 2020171606, 2020.
   Google Scholar
• Hanmi Pharm Co Ltd. Novel dioxol oisoquinolinone derivatives and use thereof. WO 2022035303, 2021.
   Google Scholar
• Southeast University. EZH2 inhibitor and preparation and application thereof. CN114621191, 2022.
   Google Scholar
• Friedman J, Cho WK, Chu CK, et al. Epigenetic Silencing of HIV-1 by the histone h3 lysine 27 methyltransferase enhancer of zeste 2. J Virol. 2011;85(17):9078–9089. DOI:10.1128/JVI.00836-11.
   PubMed Web of Science ®Google Scholar
• Glaxosmithkline Intellectual Property (NO 2. Limited. Enhancer of zeste homolog 2 inhibitors. WO 2017191545, 2017.
   Google Scholar
• Eli Lilly and Company. Inhibitors of EZH2. IN201817009082; 2018.
   Google Scholar
• Pharmablock Sciences (Nanjing) Inc. EZH2 inhibitor and use thereof. WO. 2020;2020224607.
   Google Scholar
• Pharmablock Sciences (Nanjing) Inc. New EZH2 inhibitor and use thereofp. 2022179584, 2022.
   Google Scholar
• Mirati Therapeutics Inc. EZH2 inhibitors. US20180265517; 2018.
   Google Scholar
• Novartis Ag. Aza-quinoline compounds and uses thereof. WO 2021057853, 2020.
   Google Scholar
• Novartis Ag. Quinoline compounds and compositions for inhibiting EZH2. WO2022033492, 2021.
   Google Scholar
• Epizyme Inc. Inhibitors of human EZH2, and methods of use thereof. AU 2022242157, 2022.
   Google Scholar
• Northwestern University. Substituted pyrrolidones and piperidones as small molecule inhibitors of EZH2 and EED protein binding. US 20220363633, 2022.
   Google Scholar
• Nant Holdings Ip Llc, Nantcell Inc. Subcutaneous delivery of adenovirus with dual targeting. WO 2017139725, 2017.
   Google Scholar
• Ancureall Pharmaceutical (Shanghai) Co Ltd. Histone methyltransferase EZH2 inhibitor, preparation method and pharmaceutical use thereof. WO 2018137639, 2018.
   Google Scholar
• Sichuan University. Compound for preparing targeted histone methyltransferase EZH2 covalent inhibitor as well as preparation method and application of compound. CN. 2019;112341390.
   Google Scholar
• Yat-Sen University S, Shanghai Institute of Materia Medical, Chinese Academy of Sciences. EZH2 covalent irreversible inhibitor as well as preparation method and application thereof. CN 113248481, 2021.
   Google Scholar
• Sichuan University. A covalent inhibitor of EZH2 and its preparation method and application. CN115197202, 2022.
   Google Scholar
• Zhang Q, Chen X, Cao J, et al. Discovery of a novel covalent ezh2 inhibitor based on tazemetostat scaffold for the treatment of ovarian Cancer. J Med Chem. 2023;66(3):1725–1741. DOI:10.1021/acs.jmedchem.2c01370
   PubMed Web of Science ®Google Scholar
• Wang C, Qu LL, Li S, et al. Discovery of first-in-class Dual PARP and EZH(2) inhibitors for triple-negative breast cancer with wild-type BRCA. J Med Chem. 2021;64(17):12630–12650. DOI:10.1021/acs.jmedchem.1c00567
   PubMed Web of Science ®Google Scholar
• China Pharmaceutical University. Double-target PARP/EZH2 inhibitor as well as preparation method and application thereof. CN. 2021;113024516.
   Google Scholar
• Mozzetta C, Pontis J, Fritsch L, et al. The Histone H3 Lysine 9 Methyltransferases G9a and GLP Regulate Polycomb Repressive Complex 2-Mediated Gene Silencing. Molecular Cell. 2014;53(2):277–289. DOI:10.1016/j.molcel.2013.12.005
   PubMed Web of Science ®Google Scholar
• Shenyang Pharmaceutical University. A quinazolinone compound or a medically acceptable salt thereof and a preparation method and application thereof. CN. 2022;114409636.
   Google Scholar
• Huang X, Yan J, Zhang M, et al. Targeting epigenetic crosstalk as a therapeutic strategy for EZH2-Aberrant Solid Tumors. Cell. 2018;175(1):186–199. DOI:10.1016/j.cell.2018.08.058
   PubMed Web of Science ®Google Scholar
• Huang N, Liao P, Zuo Y, et al. Design, synthesis, and biological evaluation of a potent dual EZH2-BRD4 Inhibitor for the treatment of some solid tumors. J Med Chem. 2023;66(4):2646–2662. DOI:10.1021/acs.jmedchem.2c01607
   PubMedGoogle Scholar
• West China Hospital, Sichuan University. Benzoheterocycle-pyridone derivative as well as preparation method and application thereof. CN114805350, 2022.
   Google Scholar
• Ma AQ, Stratikopoulos E, Park KS, et al. Discovery of a first-in-class EZH2 selective degrader. Nat Chem Biol. 2020;16(2):214–222. DOI:10.1038/s41589-019-0421-4.
   PubMed Web of Science ®Google Scholar
• Icahn School of Medicine at Mount Sinai. Compositions and Methods for treating EZH2-mediated cancer. WO 2018081530, 2017.
   Google Scholar
• Sichuan Haisco Pharmaceutical Co Ltd. Enhancer of zeste homolog 2 inhibitors and application thereof. CN. 2022;115197194.
   Google Scholar
• Tsinghua University. Small-molecular compound capable of degrading EZH2 protein. CN. 2020;111303133.
   Google Scholar
• West China Hospital, Sichuan University. Bifunctional compound capable of inducing PRC2 protein complex core subunit degradation, pharmaceutical composition and application. WO2021238007, 2020.
   Google Scholar
• Sun Yat-Sen University Cancer center (Sun Yat-Sen University Affiliated Cancer Hospital, Sun Yat-Sen University Cancer Inatitute). Small molecule compound based on EZH2 protein degradation, and application thereof. CN. 2020;113214203.
   Google Scholar
• Daegu Gyeongbuk Medical Innovation Found. Compound comprising EZH2 inhibitor and E3 ligase binder and pharmaceutical composition for preventing or treating EZH2-associated disease comprising same as active ingredient. WO 2021086069, 2021.
   Google Scholar
• Zhang QS, Yang HL, Feng Q, et al. Focus on the classical and non-classical functions of EZH2: guide the development of inhibitors and degraders. Pharmacol Res. 2022;178:178.
   Web of Science ®Google Scholar
• Stazi G, Zwergel C, Mai A, et al. Expert Opinion on Therapeutic Patents. Expert Opin Ther Patents. 2017;27(7):797–813. DOI:10.1080/13543776.2017.1316976
   PubMed Web of Science ®Google Scholar
• Bisserier M, Wajapeyee N. Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas. Blood. 2018;131(19):2125–2137.
   PubMed Web of Science ®Google Scholar
• Sun DH, Zhang J, Dong GQ, et al. Blocking non-enzymatic functions by PROTAC-Mediated targeted protein degradation. J Med Chem. 2022;65(21):14276–14288. DOI:10.1021/acs.jmedchem.2c01159
   PubMed Web of Science ®Google Scholar
• Ai SS, Yu XH, Li YM, et al. Divergent requirements for EZH1 in heart development versus regeneration. Circ Res. 2017;121(2):106–112. DOI:10.1161/CIRCRESAHA.117.311212
   PubMed Web of Science ®Google Scholar
• Mohammad HP, Barbash O, Creasy CL. Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. Nature Med. 2019;25(3):403–418.
   PubMed Web of Science ®Google Scholar